Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 95

Results For "PAT"

6801 News Found

RPG Life Sciences Q1FY22 PAT surges to Rs. 13.58 Cr
News | July 29, 2021

RPG Life Sciences Q1FY22 PAT surges to Rs. 13.58 Cr

The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.


Astec Lifesciences 1FY22 consolidated PAT at Rs. 12.98 Cr
News | July 29, 2021

Astec Lifesciences 1FY22 consolidated PAT at Rs. 12.98 Cr

The company posted net profit of Rs.16.18 crores for the period ended June 30, 2020.


Pfizer posts Q1FY22 PAT of Rs. 199.91 Cr
News | July 29, 2021

Pfizer posts Q1FY22 PAT of Rs. 199.91 Cr

The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.


Aarti Drugs posts Q1FY22 consolidated PAT at Rs. 48.81 Cr
News | July 28, 2021

Aarti Drugs posts Q1FY22 consolidated PAT at Rs. 48.81 Cr

The company posted net profit f Rs.85.45 crores for the period ended June 30, 2020.


Torrent Pharmaceuticals Q1FY22 consolidated PAT up at Rs. 330 Cr
News | July 28, 2021

Torrent Pharmaceuticals Q1FY22 consolidated PAT up at Rs. 330 Cr

The company posted net profit of Rs.321 crores for the period ended June 30, 2020.


Dr. Reddy's Laboratories Ltd Q1FY22 consolidated PAT at Rs. 380.4 Cr
News | July 28, 2021

Dr. Reddy's Laboratories Ltd Q1FY22 consolidated PAT at Rs. 380.4 Cr

The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.


Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | July 28, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.


Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
News | July 22, 2021

Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr

The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.


Kwality Pharmaceuticals Q4FY21 consolidated PAT higher at Rs. 8.14 Cr
News | July 04, 2021

Kwality Pharmaceuticals Q4FY21 consolidated PAT higher at Rs. 8.14 Cr

The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021


Samrat Pharmachem reports Q4 FY21 PAT at Rs. 1.55 Cr
News | July 02, 2021

Samrat Pharmachem reports Q4 FY21 PAT at Rs. 1.55 Cr

The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021